Ute Hoch, PhD 

Dr. Ute Hoch has a broad background in drug discovery and development and a passion for developing novel medicines for the right patients at the right dose. With more than 20 years of experience in the life sciences industry, Ute is a seasoned leader and expert in pharmaceutical research and development.  

During her 15 year tenure at Nektar Therapeutics, Ute held roles of increasing responsibility in the areas of pharmacology, drug metabolism and pharmacokinetics (DMPK), clinical pharmacology and translational medicine, and contributed significantly to the development and regulatory filings for more than a dozen small molecule and protein drugs across indication areas. Most recently, Ute was Vice President at Fibrogen with responsibilities for nonclinical development, clinical pharmacology and translational medicine for a diverse portfolio of innovative small and large molecules from discovery to Phase 3.  

Ute has authored and co-authored more than 50 publications. She received her doctoral degree from Julius-Maximilians-Universität Würzburg, Germany, and completed her postdoctoral research at the University of California, San Francisco.